Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13197798 | 0.87 | P2RX7 (0.45) | SMN1; SMN2MAPTL3MBTL1TP53 | |
| SCHEMBL13197785 | 0.87 | MAPT (0.38) | EPHX2SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL13197780 | 0.86 | CHRM1 (0.36) | SMN1; SMN2MAPTNPC1RAB9ASLC6A3 | |
| SCHEMBL13197804 | 0.86 | L3MBTL1 (0.36) | SMN1; SMN2MAPTNPC1RAB9ASLC6A3 | |
| SCHEMBL13197808 | 0.86 | SLC6A3 (0.37) | SMN1; SMN2MAPTNPC1RAB9ASLC6A3 | |
| SCHEMBL1595904 | 0.85 | MAPT (0.42) | SMN1; SMN2MAPTNPC1RAB9ASLC6A3 | |
| SCHEMBL13197805 | 0.83 | MAPT (0.39) | SMN1; SMN2MAPTNPC1RAB9ASLC6A3 | |
| SCHEMBL13197812 | 0.83 | KMT2A (0.49) | EPHX2SMN1; SMN2MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL13197927 | 0.80 | LMNA (0.46) | SMN1; SMN2MAPTNPC1ALDH1A1GAA | |
| SCHEMBL13197783 | 0.79 | SLC6A3 (0.39) | SMN1; SMN2MAPTNPC1RAB9ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767704-B2 | Antiviral 4-aminocarbonylamino-substituted imidazole compounds | AICURIS GMBH & CO. KG (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | BAYER HEALTHCARE AG (DE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004275-A1 | Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds | IRF3, EIF2AK2, ZC3HAV1 | EPHX2 3922/4885SMN1; SMN2 2449/4885MAPT 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.